The meta-analysis results revealed an ORR of 0.40 (95% CI 0.29–0.51) and a CRR of 0.21 (95% CI 0.14–0.31) for PD-1/PD-L1 inhibitors in treating R/R DLBCL, consistent with the findings of Ding et al.’s study [39]. This evidence concerns the gene PDCD1 and diffuse large B-cell lymphoma.